MedTrace Logo

Remicade in the Treatment of Patients With Active Ankylosing Spondylitis

NCT01850121 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2016-08-09

No results posted yet for this study

Summary

The aim of the study was to evaluate the efficacy of infliximab (IFX) treatment, 5 mg/kg every 6 weeks, in patients with active ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension, 3 mg/kg every 8 weeks during the second year sustained the treatment effect. The study was started in 2003 an finished in 2008.

Conditions

Interventions

DRUG

Infliximab

5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.

Sponsors & Collaborators

  • Göteborg University

    lead OTHER

Principal Investigators

  • Boel Morck, MD · Sahlgrenska University Hospital

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01850121 on ClinicalTrials.gov